trending Market Intelligence /marketintelligence/en/news-insights/trending/d-fHDbABXZ1DFnrgYE3gMA2 content esgSubNav
In This List

Phylogica, Genentech to continue research collaboration, license deal

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Phylogica, Genentech to continue research collaboration, license deal

Australian drug discovery company Phylogica Ltd. and Roche Holding Ltd.'s Genentech extended the exclusivity period of a research collaboration and license agreement for the discovery of novel antibiotics.

The collaboration utilizes Phylogica's Phylomer drug discovery platform, including its proprietary cell penetrating peptide discovery technology.

As part of the deal, Phylogica will receive a $2 million milestone payment. Phylogica is also eligible to receive research, development and commercialization milestone payments of up to $142 million, in accordance with a 2014 agreement.